recent publications

• academic article

  • Chun, J., Brinkmann, V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya) Discovery Medicine  2011 64:213-228  PMID:21955849  PMCID:PMC3694567
  • Salomone, S., Potts, E. M., Tyndall, S., Ip, P. C., Chun, J., Brinkmann, V., Waeber, C. Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools British Journal of Pharmacology  2008 153:140-147  DOI:10.1038/sj.bjp.0707581  PMID:18026125  PMCID:PMC2199385
  • Walter, D. H., Rochwalsky, U., Reinhold, J., Seeger, F., Aicher, A., Urbich, C., Spyridopoulos, I., Chun, J., Brinkmann, V., Keul, P., Levkau, B., Zeiher, A. M., et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor Arteriosclerosis, Thrombosis, and Vascular Biology  2007 27:275-282  DOI:10.1161/01.atv.0000254669.12675.70  PMID:17158356
  • Tolle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schonfelder, G., Schafers, M., Lipinski, K. V., Jankowski, J., Jankowski, V., Chun, J., Zidek, W., et al. Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3 Circulation Research  2005 96:913-920  DOI:10.1161/01.res.0000164321.91452.00  PMID:15802614